Stryker Co. (NYSE:SYK) is Villere ST Denis J & Co. LLC’s 2nd Largest Position

Villere ST Denis J & Co. LLC lessened its holdings in shares of Stryker Co. (NYSE:SYK) by 2.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 138,875 shares of the medical technology company’s stock after selling 3,562 shares during the period. Stryker accounts for approximately 4.1% of Villere ST Denis J & Co. LLC’s investment portfolio, making the stock its 2nd biggest position. Villere ST Denis J & Co. LLC’s holdings in Stryker were worth $50,170,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of SYK. Norden Group LLC acquired a new stake in Stryker in the 1st quarter valued at approximately $280,000. Central Pacific Bank Trust Division acquired a new stake in Stryker in the 1st quarter valued at approximately $39,000. Envestnet Portfolio Solutions Inc. increased its holdings in Stryker by 43.1% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 18,491 shares of the medical technology company’s stock valued at $6,617,000 after purchasing an additional 5,565 shares during the last quarter. Empowered Funds LLC increased its holdings in Stryker by 74.4% in the 1st quarter. Empowered Funds LLC now owns 6,938 shares of the medical technology company’s stock valued at $2,483,000 after purchasing an additional 2,960 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in Stryker by 14.5% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 855 shares of the medical technology company’s stock valued at $306,000 after purchasing an additional 108 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In related news, insider Viju Menon sold 600 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Viju Menon sold 600 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP M Kathryn Fink sold 2,121 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00. Following the completion of the sale, the vice president now directly owns 10,042 shares in the company, valued at $3,715,540. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 67,381 shares of company stock worth $24,825,275 over the last ninety days. 5.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on SYK shares. Citigroup lifted their target price on shares of Stryker from $406.00 to $411.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Needham & Company LLC raised their price target on shares of Stryker from $393.00 to $409.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Truist Financial raised their price target on shares of Stryker from $370.00 to $380.00 and gave the company a “hold” rating in a research report on Wednesday, October 30th. UBS Group raised their price target on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Finally, Piper Sandler reissued an “overweight” rating and issued a $420.00 price target (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $393.65.

Stryker Trading Up 1.7 %

NYSE SYK opened at $375.96 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a market cap of $143.32 billion, a PE ratio of 40.30, a P/E/G ratio of 2.78 and a beta of 0.91. Stryker Co. has a one year low of $266.93 and a one year high of $377.83. The firm’s fifty day moving average is $361.46 and its two-hundred day moving average is $345.63.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same period in the previous year, the business posted $2.46 earnings per share. The business’s revenue was up 11.9% compared to the same quarter last year. Analysts expect that Stryker Co. will post 12.06 earnings per share for the current year.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.